Physician

Aiwu Ruth He, MD, PHD

According to 2025 Medicare claims, Aiwu He, MD, PHD (NPI: 1942306360) practices medical oncology in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from New York, NY. This provider's primary affiliated billing organization is TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (NPI: 1861907321; TIN: 135598093) and primary practice location at 10032-3729.

He's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 114 traditional Medicare patients, billed 426 HCPCS/CPT codes, and received $43,505 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 411 prescription claims across 71 beneficiaries totaling $623,771 in drug costs, led by Stivarga (Regorafenib). DME data shows 29 claims. Open Payments data shows 123 records totaling $982,040. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $330,096 and ending at $623,771. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $1,821 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	111	357	$35,375
2016	162	569	$55,658
2017	154	580	$56,668
2018	165	603	$56,977
2019	194	627	$50,102
2020	160	542	$41,953
2021	152	555	$62,579
2022	145	537	$58,914
2023	140	476	$51,054
2024	114	426	$43,505

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	42	285	$330,096
2016	57	430	$704,692
2017	61	479	$503,534
2018	64	481	$702,645
2019	69	535	$1,567,505
2020	59	400	$764,412
2021	65	460	$954,781
2022	66	457	$1,760,791
2023	58	413	$1,402,544
2024	71	411	$623,771

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	212	$28,456
2017	N/R	182	$21,932
2018	N/R	15	$4,388
2019	24	49	$6,096
2020	N/R	63	$6,692
2021	N/R	37	$4,097
2022	N/R	75	$26,252
2023	N/R	28	$7,573
2024	N/R	29	$867

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	27	27	$161
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	41	146	$123
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	93	205	$86
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	15	18	$15

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Stivarga	Regorafenib	14	392	$161,788
Sorafenib	Sorafenib Tosylate	11	330	$58,980
Creon	Lipase/Protease/Amylase	14	580	$13,864
Eliquis	Apixaban	19	630	$11,693
Oxycodone Hcl	Oxycodone Hcl	60	1,721	$958

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	17	$660
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	12	$207

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	66	$72,343	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	57	$909,697	Genentech, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Aiwu Ruth He, MD, PHD?

Tedicare shows public-source Medicare data for Aiwu Ruth He, MD, PHD (NPI 1942306360), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Aiwu Ruth He, MD, PHD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Aiwu Ruth He, MD, PHD?

Aiwu Ruth He, MD, PHD is linked to TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (billing NPI 1861907321) in the available physician profile data.

Does Aiwu Ruth He, MD, PHD have Open Payments data?

Aiwu Ruth He, MD, PHD has 123 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.